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l’Université de Montréal, Montréal, Quebec, Canada; and {{{{{Department of Basic Medical Sciences,
Center for Applied Nanobioscience and Medicine, College of Medicine Phoenix, University of Arizona,
Phoenix, ArizonaReceived Dec 22, 2013, and in revised form Feb 19, 2014. Accepted for publication Mar 6, 2014.Radiogenomics is the study of the link between germ line
genotypic variations and the large clinical variability
observed in response to radiation therapy. The radio-
genomics hypothesis is that a proportion of the variance in
the phenotype of interestdradiation toxicitydis explained
by genotypic variation. Thus, the aim of radiogenomics is
to identify the alleles that underlie the inherited dissimi-
larities in phenotype. However, this hypothesis does not
assume that all of the phenotypic differences are due to
germ line genetic alterations, but it acknowledges that
epigenetic changes (inherited and acquired) and other fac-
tors could also be important.
To foster collaborative research, the Radiogenomics
Consortium (RGC) was established in 2009 (1). The RGC
currently has 174 members from 90 institutions in 20
countries and is a cancer epidemiology consortiumsupported by the National Cancer Institute (NCI) (2). The
goal of the RGC is to facilitate large-scale collaborative
research assessing geneeradiation effect relationships,
including genome-wide association studies (GWAS). The
aim of this research is to produce assays for use in the clinic
to predict risk of toxicities after radiation therapy, given
alone or in multimodality treatments. The results of this
research could also lead to the identification of novel
strategies for prevention or mitigation of toxicities.
Currently, the radiogenomics landscape is rapidly
changing. This is partly a result of research advances within
the field of radiogenomics itself and partly due to progress
in biotechnology and medical informatics that facilitate the
pursuit of novel discovery strategies. Radiogenomics is
now rapidly advancing from an effort to screen a limited
number of candidate genes toward an open discovery
Volume 89  Number 4  2014 Radiogenomics 711approach or, from relatively small studies conducted by a
few scientists to the potentially powerful, but challenging,
era of big data and team science.
However, the substantial progress in radiogenomics may
be largely unnoticed by the broader radiation therapy
community, leading to underestimation of its potential for
improving patient outcomes. Therefore, it is critical to
address the following questions at this stage in the devel-
opment of research in radiogenomics.What Have We Learned From Candidate Gene
Studies?
The pioneering radiogenomics studies conducted over the
past decade were hypothesis driven. The underlying
hypothesis took advantage of a considerable body of
knowledge about genes involved in the recognition and
repair of DNA damage and the molecular biology of
normal tissue response and remodeling after exposure to
ionizing radiation. The candidate gene hypothesis was that
single-nucleotide polymorphisms (SNPs) could cause a
patient-specific variability in the level or function of pro-
teins involved in radiation damage processing. The early
studies were hypothesis generating and initially found
numerous SNPs associated with variability in radiosensi-
tivity. However, it has not been possible to validate the
association with radiation toxicity for any of the approxi-
mately 100 SNPs that were identified by use of the candi-
date gene approach (3, 4). Most researchers therefore
concur that the candidate gene studies tell us that common
sequence alternations in the most obvious genes are un-
likely to explain a significant fraction of patient-to-patient
variability in radiation response. However, any study will
have statistical power to detect only an association of a
given minimum effect size. This means that we cannot rule
out that SNPs in candidate genes have some effect on the
risk of toxicity, but it appears safe to say that there are now
sufficient data to rule out large effect sizes in the most
obvious candidate genes.Have the Goals of Radiogenomics Been
Achieved Through the Performance of GWAS?
The GWAS approach being pursued in radiogenomics
provides a new path toward the creation of predictive as-
says that can be incorporated into routine clinical care.
However, this goal has not yet been achieved in radio-
genomics because: (1) cohorts have only recently become
large enough to have the power to identify genetic variants
with a minor allele frequency above 5% and associated
with clinically relevant odds ratios for the development of
a given effect in the range of 1.2 to 1.5 at stringent levels
of statistical significance (P<5  108); and (2) the as-
sociations identified have not been tested rigorously in
independent validation studies. Ongoing RGC research isaddressing these 2 important limitations by moving from
single-institution studies to multinational team science.
Recent studies show that many genetic associations will
be identified with the use of large multisite cohorts and
contemporary techniques of tagging SNPs, imputation,
and meta-analysis (3). It is noteworthy that the NCI has
embraced this multisite, multicohort GWAS approach as
the key to identifying genetic risks for cancer and treat-
ment outcomes through their support of the Genetic As-
sociations and Mechanisms in Oncology (GAME-ON)
initiative (5). Radiogenomics research follows a similar
approach.
Has the Validity of GWAS for Identifying
Genetic Variations Responsible for Human
Disease Been Proved?
GWAS provide a comprehensive and unbiased assessment
of SNPs across the genome and test for their association
with disease phenotypes. However, the validity of GWAS
in identifying genetic variations responsible for human
disease is not universally accepted (6), and there are
divergent views about the clinical relevance and utility of
the associated SNPs (7). However, there is no doubt that
GWAS have revolutionized the identification of common
genetic variations reported as SNPs associated with
human traits and disease susceptibility. Since 2005,
GWAS have identified approximately 2000 new human
trait/disease susceptibility loci (8). For example, analysis
of approximately 50,000 patients with prostate cancer and
control individuals identified more than 70 cancer sus-
ceptibility loci, explaining approximately 30% of the fa-
milial risk for this disease; the top 1% of the risk
distribution having a 4.7-fold increased risk of prostate
cancer (9). Another illustration of the success of GWAS
was the identification of a variant associated with an
increased risk for the development of second malignant
neoplasms in survivors of Hodgkin lymphoma treated with
radiation therapy. The variant is common and penetrant,
but only in the context of radiation; thus, it has potential to
contribute to clinical decision making (10). In parallel,
RGC investigators are making substantial progress to
identify SNPs associated with radiation toxicity, particu-
larly because the sample sizes and therefore statistical
power of radiogenomics studies are increasing markedly
(3).
Are GWAS Likely to Identify Biologically
Relevant Causal Relationships?
A frequently aired misconception is that GWAS have pri-
marily identified common variants that are statistically
correlated with various conditions but that have no estab-
lished biological function and may even be located in
noncoding regions of the genome and therefore not be of
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continues along the line that these genetic alterations
represent false positive results, whereas rare variants with a
high level of phenotypic penetrance are responsible for
most inherited disease susceptibility. It may be correct that
rare mutations could be responsible for a significant pro-
portion of human disease, but this does not preclude an
important effect of common variants. Although the
“missing heritability” not explained by identified variants
following the common diseaseecommon variant model
leaves room for the common disease-rare allele model, it is
generally considered that both models are valid and com-
plementary (12). As a demonstration that these 2 concepts
are not mutually exclusive, it should be noted that once the
common functional variants driving a significant SNP as-
sociation have been discovered through a GWAS, rarer
variants with similar modes of action are frequently found
within the same locus (13). Furthermore, there is no
fundamental problem in the fact that most SNP associations
were identified without prior knowledge of biological
function (8). Also, the argument that common variants
associated with disease are inconsequential because they lie
in noncoding regions of DNA is countered by the ENCODE
project, which has clearly demonstrated that this portion of
the genome is functionally significant (14). In addition, the
functional mechanisms for specific SNPs located in non-
coding regions have now been confirmed (15). New post-
GWAS studies are beginning to show that many SNPs
associated with complex diseases act in a trans manner,
wherein the SNP affects the expression of a gene that lies in
a completely different locus (16).
Should the Emphasis of Research in
Radiogenomics Be on the Performance of
Mechanistic Studies?
A question can be posed as to whether the focus of research
in radiogenomics should now be shifted to functional
studies to determine how SNPs affect the radiation re-
sponses of normal tissues. Although mechanistic studies are
important, this direction in research is premature until the
SNPs associated with radiosensitivity have been validated
with a high level of certainty and fine mapping has been
performed to identify the causative variants. Also, before
the achievement of a complete understanding of the
mechanism underlying an effect, prediction in clinical
medicine can still be of great importance. Although it could
take many years to complete the functional studies needed
to characterize the biological mechanism underlying SNPs
found to be associated with radiation therapy toxicity, this
piece of the puzzle is not necessarily required for the pur-
pose of developing predictive models. In traditional
epidemiology, many known risk factors play an important
role in prevention and screening programs, even though the
precise mechanisms linking them with disease are poorly
understood.Can We Conduct the Large Clinical Studies
Required?
GWAS require very large sample sizes to ensure resolution
of clinically relevant effect sizes while keeping the proba-
bility of false positive findings low. Virtually all data for
patients included in published radiogenomics studies were
obtained prospectively by the use of validated instruments
for recording and grading toxicities. One challenge is
pooling data collected using different toxicity recording
dictionaries, radiation therapy delivery platforms, and pa-
tient populations (17). This requires large collaborative
teams of clinicians, nurses, biologists, medical physicists,
data managers, biostatisticians, and bioinformaticiansdie,
team science! However, an issue that could be raised is
whether this heterogeneity confounds the results of GWAS
based on such studies (18) and whether the predictive
ability of the genetic markers is generalizable for different
radiation therapy approaches. In this light, it is reassuring to
note that despite these variations, SNPs have been discov-
ered that are associated with toxicities and replicate in in-
dependent cohorts involving treatment with multiple forms
of radiation therapy (3, 19). The discovery of genetic
markers that apply to patients independently of radiation
therapy schedules is particularly important because it
demonstrates that the assays being developed by RGC in-
vestigators will be applicable across radiation therapy
modalities. With this in mind, it can be argued that the
diversity of radiation therapy approaches in the RGC co-
horts needs to be embraced, rather than avoided, to ulti-
mately decide which treatment is best for each individual
patient (20).
It should be noted that even though SNPs have been
successfully identified in cohorts treated under multiple
protocols, the RGC is working toward the standardization
of toxicity data collection through publication of a rec-
ommended common set of guidelines for reporting radi-
ogenomic studies (21). In addition, through a project
funded by the European Union, RGC investigators are
collecting detailed treatment, comorbidity, and toxicity
data prospectively for 5300 patients with prostate, breast,
or lung cancer undergoing radiation therapy in a multi-
center study using identical treatment and toxicity data
collection forms.What Is the Potential Clinical Utility of
Radiogenomics?
Tumor eradication is the primary aim of radiation therapy.
However, with an increasing number of long-term cancer
survivorsdmany of whom received radiation therapydthe
impact of radiation-induced injuries on health-related
quality of life is a growing concern. Moreover, research
on the use of patient decision aids supports the concept that
where choices for therapy exist, information that supports a
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of treatment options encourages more active involvement
of patients in decision making, resulting in decreased
anxiety and decision regret.
In addition, the risk of severe toxicity in a minority of
patients limits the potentially curative doses prescribed to
the majority. Modeling studies support the hypothesis that
identification of patients with a low risk for the develop-
ment of adverse effects should allow for dose escalation
and improvements in tumor control. Radiogenomics has
therefore focused initially on the identification of SNPs
associated with radiation therapy toxicity.
It is clear that the development and application of a set
of genetic biomarkers is indeed the epitome of patient-
centered oncology care. However, better alignment of pa-
tient needs and provision of information by physicians will
be required to achieve this goal. Shared decision making
between patients and their radiation oncologists that bal-
ances the probabilities of freedom from disease progression
with freedom from toxic normal tissue effects is increas-
ingly desired by patients, providers, and insurers alike (22).
A set of validated biomarkers should therefore become part
of a patient decision aid that incorporates patient values
into a personalized radiation treatment approach (23).
However, as has been recognized (6), there are significant
obstacles to the routine clinical use of such biomarkers,
inasmuch as their implementation would require clear in-
terest and support from physicians, patients, and insurance
companies; unfortunately, the incentive structure is not
clearly aligned with achieving this goal.
In summary, collaborative efforts in radiogenomics
fostered through the RGC are underpinning progress in
identifying genetic variants that predict the risk of toxicity
after radiation therapy. Radiogenomics investigators have
already proved that we have the team to deliver the large
data sets required. It is the nature of research that the end
result can never be guaranteed, but what we can guarantee is
the quality of our science. The research currently under way,
which uses state-of-the-art techniques used successfully in
genetic studies of other complex phenotypes, may well lead
to the development of predictive assays ready for imple-
mentation in the routine clinical care of cancer patients.
Thus, in the future, it is anticipated that genetic profiling will
play a critical role in helping to guide cancer patients and
their doctors to select the best treatment approach or radia-
tion therapy dose for each individual.
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